newsfilter
← Latest News
PR Newswire·

Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

-- VANQUISH Phase 3 Trials for Subcutaneous VK2735 in Obesity Continue to Advance ---- SUNRISE Phase 3 Trials for Oral VK2735 Initiated ---- Positive Top-Line Results Announced for VK2735 Maintenance Dosing Study; Part